Trade Mark Journal No.2026/039 25 September 2026

WO0000001937613 (5,42)

Office of origin: European Union Intellectual Property Office (EUIPO)

Date of International Registration:7 July 2026
Date of designation in the UK: 7 July 2026
Image for mark 1937613_TIF Threepoint

International priority date claimed: 16 January 2026 (European Union Intellectual Property Office (EUIPO)) (019304397)
Class 5
Drugs for medical purposes; medicines for human purposes; pharmaceutical preparations; chemical preparations for pharmaceutical purposes; DNA and RNA for medical purposes; antibiotics; antivirals.
Class 42
Research and development services in the field of pharmaceuticals and drug discovery; development of processes and methods for medical and veterinary purposes; development of preparations for medical and veterinary purposes; scientific research for medical purposes, namely, screening for the identification of drug candidates; development of precision RNA therapeutics; development of tailored RNA-based corrective interventions to target the root causes of serious diseases; research and development of new medical products for others; development and identification of novel druggable sites for pharmacological intervention using a bioinformatic discovery platform in a wet lab; screening services, bioinformatics services and modeling services to harness natural processes and modulate gene expression through platforms to generate optimized small molecules, antisense oligonucleotides (ASOs) and small interfering RNAs (siRNAs); designing and implementing multiplexed high-throughput assays to screen for small molecules that modulate RNA processing using bioinformatic tools; designing and developing algorithms and thermodynamic models.

Contera Pharma A/S

Representative: DE FRIES & TUFEKOVIC IP APS, Bredgade 30, DK-1260 Copenhagen K, DENMARK